PHASE IB STUDY OF CC‐122 IN COMBINATION WITH OBINUTUZUMAB (GA101): RELAPSED OR REFRACTORY (R/R) PATIENTS WITH B‐CELL NON‐HODGKIN LYMPHOMAS (NHL)

Introduction: CC-122 is a cereblon modulating agent with promising clinical activity in FL and DLBCL. Preclinically, CC-122 with obinutuzumab has improved activity vs either single agent. Methods: This phase Ib study (EUDRACT 2014-003333-26; NCT02417285) evaluates CC-122 plus obinutuzumab in patients with CD20+ R/R B-cell NHL. Patients with FL/MZL had ≥1 prior regimens, or ≥2 regimens ± ASCT for DLBCL. Oral CC-122 was given (5 of 7d for 28-d...